Security Snapshot

Pharvaris N.V. - Ordinary shares, par value Euro 0.12 per share (PHVS) Institutional Ownership

CUSIP: N69605108

13F Institutional Holders and Ownership History from Q1 2021 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

42

Shares (Excl. Options)

8.99MFull value: 8,987,291 · shares · 30 Sep 2026

Price

$31.72

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-3,775,682
Value change
-$120,470,624
Number of holders
42
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
72,909,667
SEC-reported price per share
$31.72
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • PHVS - Pharvaris N.V. - Ordinary shares, par value Euro 0.12 per share is tracked under CUSIP N69605108.
  • 42 institutions reported positions in Q3 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 125 to 42 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $2.23BFull value: $2,230,617,690 · USD · 30 Jun 2026
    to
    $285.08MFull value: $285,077,353 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 42 institutions filings for Q3 2026.

Open SEC evidence

Security key

N69605108

13F reference period

Q3 2026

13F holders

42

13D/G owners

5

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
PHVS
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VIKING GLOBAL INVESTORS LP 5.6% $103,206,008 3,653,310 VIKING GLOBAL INVESTORS LP 31 Mar 2026
LSP V Cooperatieve U.A. 4.9% $118,457,225 3,424,609 LSP V Cooperatieve U.A. 30 Jun 2026
Venrock Healthcare Capital Partners III, L.P. 3.8% $51,436,214 2,047,620 Venrock Healthcare Capital Partners III, L.P. 30 Jun 2025
Bain Capital Life Sciences Fund, L.P. 2.5% -17% $41,020,425 -$5,670,300 1,640,817 -12% Bain Capital Life Sciences Fund, L.P. 31 Dec 2025
GENERAL ATLANTIC, L.P. 0.6% -88% $13,876,168 -$156,134,373 437,458 -92% GENERAL ATLANTIC, L.P. 30 Sep 2026
As of 30 Sep 2026, 42 institutional investors reported holding
8.99MFull value: 8,987,291 · shares · 30 Sep 2026
shares of Pharvaris N.V. - Ordinary shares, par value Euro 0.12 per share (PHVS). This represents 12% of the company’s total
72.91MFull value: 72,909,667 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
12%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
EQT Fund Management S.a r.l. 4.7% 3,424,609 0% 11% $108,628,597
GENERAL ATLANTIC, L.P. 2.3% 1,651,490 -75% 2.1% $52,385,263
Jones Hill Capital LP 1.4% 987,637 +46% 5.3% $31,327,846
Patient Square Capital LP 1.1% 808,644 +20% 4.1% $25,650,188
MORGAN STANLEY 0.57% 412,829 +324% 0% $13,094,937
NEXTBio Capital Management LP 0.51% 372,552 +245% 5% $11,817,349
Qube Research & Technologies Ltd 0.39% 282,873 +102% 0.01% $8,972,732
STATE STREET CORP 0.21% 151,411 -10% 0% $4,802,757
Nantahala Capital Management, LLC 0.21% 150,000 0.27% $4,758,000
HighVista Strategies LLC 0.17% 126,174 -21% 1.1% $4,002,240
GEODE CAPITAL MANAGEMENT, LLC 0.12% 89,256 -0.73% 0% $2,830,803
TD ASSET MANAGEMENT INC 0.1% 71,226 +85% 0% $2,260,001
DEUTSCHE BANK AG\ 0.08% 61,123 +14% 0% $1,938,822
Swiss National Bank 0.07% 49,457 +26% 0% $1,568,776
Jump Financial, LLC 0.06% 44,100 0.01% $1,398,852
Amundi 0.06% 43,127 -14% 0% $1,367,988
MANUFACTURERS LIFE INSURANCE COMPANY, THE 0.06% 40,303 +70% 0% $1,278,411
Birchview Capital, LP 0.04% 29,847 0% 0.55% $946,747
Palumbo Wealth Management LLC 0.04% 29,413 +40% 0.19% $932,981
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 0.03% 21,735 -6% 0% $689,434
VANGUARD ASSET MANAGEMENT, Ltd 0.03% 19,358 +29% 0% $614,036
China Universal Asset Management Co., Ltd. 0.02% 16,510 +12% 0.03% $523,862
Y-Intercept (Hong Kong) Ltd 0.02% 13,738 -66% 0.01% $435,769
OpenArc Corporate Advisory, LLC 0.02% 13,595 0% 0% $431,233
TEACHER RETIREMENT SYSTEM OF TEXAS 0.02% 12,827 +52% 0% $406,873

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
23
Headline period
Q3 2026
Rows shown
1-23 of 23
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 8,987,291 $285,077,353 -$120,470,624 $31.72 42
2026 Q2 64,507,647 $2,230,617,690 +$199,563,652 $34.58 125
2026 Q1 58,921,412 $1,664,385,298 -$6,360,608 $28.25 110
2025 Q4 59,040,212 $1,638,008,634 +$19,048,600 $27.75 107
2025 Q3 57,844,608 $1,443,142,875 +$236,461,176 $24.95 83
2025 Q2 45,040,180 $792,712,813 +$1,806,103 $17.60 60
2025 Q1 44,939,067 $705,543,867 +$4,132,739 $15.70 52
2024 Q4 44,644,168 $855,824,077 -$7,190,155 $19.17 54
2024 Q3 45,045,428 $834,243,398 +$34,119,580 $18.52 51
2024 Q2 43,008,763 $808,565,649 +$10,680,383 $18.80 36
2024 Q1 42,425,740 $980,459,437 +$36,728,417 $23.11 35
2023 Q4 40,745,703 $1,142,917,292 +$327,949,428 $28.05 36
2023 Q3 29,067,102 $606,630,419 +$4,468,799 $20.87 21
2023 Q2 28,913,752 $441,577,880 +$109,619,000 $15.14 21
2023 Q1 21,781,494 $173,888,454 +$3,756,313 $8.06 21
2022 Q4 21,301,855 $239,644,411 -$1,830,525 $11.25 25
2022 Q3 22,314,954 $173,600,000 -$317,120 $7.67 21
2022 Q2 22,353,338 $494,009,000 +$14,911,660 $22.10 20
2022 Q1 21,685,388 $397,090,000 +$838,867 $18.14 22
2021 Q4 21,647,018 $321,068,000 -$1,695,268 $14.39 22
2021 Q3 21,631,638 $380,302,000 -$6,827,497 $17.73 25
2021 Q2 21,995,815 $406,288,000 -$1,442,853 $18.62 28
2021 Q1 22,025,122 $616,507,000 +$616,507,000 $27.99 33
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .